Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenfluramine and Cannabidiol in Dravet or Lennox-Gastaut Syndrome
NCT03467113Phase 1Completed
- Sponsor
- Zogenix, Inc.
- Start
- Jan 2018
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fenfluramine in Dravet syndrome and Lennox-Gastaut syndrome (LGS), sponsored by Zogenix, Inc. Primary endpoints: Adverse Events at 365 days, Change in Heart Rate at 365 days and 6 more. Started Jan 2018; status: completed.
02
Drugs
fenfluramine
03
Conditions
Dravet syndromeLennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on NCT03467113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03467113.